Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
Grant Opportunity Analysis
The National Institutes of Health (NIH) is offering funding through the Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) to support the preclinical and early-stage clinical development of innovative drug candidates aimed at preventing, slowing, or treating Alzheimer's disease (AD). This program specifically seeks proposals for activities such as medicinal chemistry, pharmacokinetics, biomarker development, and initial Phase I clinical testing, with an emphasis on rigor, reproducibility, and diversity in clinical trial participation. As the U.S. faces a projected increase in AD cases, this funding opportunity is crucial for fostering advancements in treatment solutions while ensuring compliance with regulatory pathways for FDA approval. Interested applicants can submit proposals starting January 3, 2025, with a funding ceiling of $1.5 million and a project duration of up to five years for early-stage projects. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
Eligible Applicants
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.